| Original language | English |
|---|---|
| Article number | 92 |
| Number of pages | 3 |
| Journal | Blood Cancer J. |
| Volume | 10 |
| Issue number | 9 |
| DOIs | |
| Publication status | Published - 2020 |
Keywords
- B lymphocyte receptor
- idelalisib
- rituximab
- allogeneic stem cell transplantation
- cancer growth
- cancer staging
- chronic lymphatic leukemia
- clinical outcome
- follow up
- human
- Letter
- multivariate logistic regression analysis
- overall survival
- patient coding
- predictive value
- risk algorithm
- scoring system
- survival analysis
- univariate analysis
- validation study
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib–rituximab : Blood Cancer Journal. / Gentile, M.; Martino, E.A.; Visentin, A.; Coscia, M.; Reda, G.; Sportoletti, P.; Mauro, F.R.; Laurenti, L.; Varettoni, M.; Murru, R.; Chiarenza, A.; Vigna, E.; Mendicino, F.; Lucia, E.; Bossio, S.; Recchia, A.G.; Moia, R.; Pietrasanta, D.; Loseto, G.; Consoli, U.; Scortechini, I.; Rossi, F.M.; Zucchetto, A.; Al-Janazreh, H.; Vitale, C.; Tripepi, G.; D’Arrigo, G.; Angeletti, I.; Bomben, R.; Neri, A.; Cutrona, G.; Fronza, G.; Di Raimondo, F.; Gaidano, G.; Cuneo, A.; Foà, R.; Ferrarini, M.; Trentin, L.; Gattei, V.; Morabito, F.
In: Blood Cancer J., Vol. 10, No. 9, 92, 2020.Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib–rituximab
T2 - Blood Cancer Journal
AU - Gentile, M.
AU - Martino, E.A.
AU - Visentin, A.
AU - Coscia, M.
AU - Reda, G.
AU - Sportoletti, P.
AU - Mauro, F.R.
AU - Laurenti, L.
AU - Varettoni, M.
AU - Murru, R.
AU - Chiarenza, A.
AU - Vigna, E.
AU - Mendicino, F.
AU - Lucia, E.
AU - Bossio, S.
AU - Recchia, A.G.
AU - Moia, R.
AU - Pietrasanta, D.
AU - Loseto, G.
AU - Consoli, U.
AU - Scortechini, I.
AU - Rossi, F.M.
AU - Zucchetto, A.
AU - Al-Janazreh, H.
AU - Vitale, C.
AU - Tripepi, G.
AU - D’Arrigo, G.
AU - Angeletti, I.
AU - Bomben, R.
AU - Neri, A.
AU - Cutrona, G.
AU - Fronza, G.
AU - Di Raimondo, F.
AU - Gaidano, G.
AU - Cuneo, A.
AU - Foà, R.
AU - Ferrarini, M.
AU - Trentin, L.
AU - Gattei, V.
AU - Morabito, F.
N1 - Cited By :1 Export Date: 19 February 2021 Correspondence Address: Gentile, M.; Hematology Unit AO of CosenzaItaly; email: massim.gentile@tiscali.it Correspondence Address: Morabito, F.; Biothecnology Research Unit, Italy; email: f.morabito53@gmail.com Correspondence Address: Gattei, V.; Clinical and Experimental Onco-Hematology Unit, Italy; email: vgattei@cro.it Chemicals/CAS: idelalisib, 1146702-54-6, 870281-82-6; rituximab, 174722-31-7 Funding details: Fondazione Cassa di Risparmio di Calabria e Lucania, 16695 Funding details: Ministero della Salute, PE-2016-02362756 Funding details: Associazione Italiana per la Ricerca sul Cancro, AIRC, 9980, IG-14326, IG-21687, RF-2018-12365790 Funding text 1: Associazione Italiana Ricerca sul Cancro (AIRC) Grant 5× mille no. 9980 (to F.M., M.F., and A.N.), AIRC and Fondazione CaRiCal cofinanced Multi-Unit Regional Grant 2014 no. 16695 (to F.M.) Associazione Italiana Ricerca Cancro (AIRC), Investigator Grant IG-21687 (to V.G.), IG-14326 (to M.F.), Progetto Ricerca Finalizzata PE-2016-02362756 (to V.G.) and RF-2018-12365790 (to A.Z.), Ministero della Salute, Rome, Italy, Progetto Ricerca Finalizzata PE 2016-02362756, Ministero della Salute, Rome, Italy (to V.G.), and by the Italian Ministry of Health 5×1000 funds 2015 and 2016 and Current Research 2016 (to G.C.). Funding of the project was provided by an unrestricted contribution from GILEAD Sciences Srl. The funding sources had no role in identifying statements, abstracting data, synthesizing the results, grading evidence, or preparing the paper, or in the decision to submit the paper for publication (ISR-17-10250). References: Gentile, M., Survival-risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib (2020) A Campus CLL Study. Leukemia, , https://doi.org/10.1038/s41375-020-0833-x; Soumerai, J.D., Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations (2019) Lancet Haematol., 6, pp. e366-e374; Furman, R.R., Idelalisib and rituximab in relapsed chronic lymphocytic leukemia (2014) N. Engl. J. Med., 370, pp. 997-1007. , COI: 1:CAS:528:DC%2BC2cXkvVyqtLs%3D; Sharman, J.P., Final results of a randomized, phase III study of rituximab with or without idelalisib followed by open-label idelalisib in patients with relapsed chronic lymphocytic leukemia (2019) J. Clin. Oncol., 37, pp. 1391-1402. , COI: 1:CAS:528:DC%2BC1MXhvVSntrjN
PY - 2020
Y1 - 2020
KW - B lymphocyte receptor
KW - idelalisib
KW - rituximab
KW - allogeneic stem cell transplantation
KW - cancer growth
KW - cancer staging
KW - chronic lymphatic leukemia
KW - clinical outcome
KW - follow up
KW - human
KW - Letter
KW - multivariate logistic regression analysis
KW - overall survival
KW - patient coding
KW - predictive value
KW - risk algorithm
KW - scoring system
KW - survival analysis
KW - univariate analysis
KW - validation study
U2 - 10.1038/s41408-020-00358-3
DO - 10.1038/s41408-020-00358-3
M3 - Article
VL - 10
JO - Blood Cancer J.
JF - Blood Cancer J.
SN - 2044-5385
IS - 9
M1 - 92
ER -